RVMD
Revolution Medicines, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+40/100
Last price
199.20
▼ 8.48 (4.08%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
207.68
Prev close
207.68
Day high
208.57
Day low
195.00
Volume
1.63M
Market cap
$42.84B
P/E (TTM)
—
52W range
45.80 – 224.31
Day trading desk
Gap from prior close
+0.00%
Prior close 207.68
VWAP
199.47
-0.13% from price
Relative volume
0.77×
Normal
Session range
7.69%
195.00 – 210.00
Position in range
28%
Near session low
ATR (14D)
7.67
3.85% of price
Prior day high
210.27
PDH
Prior day low
201.83
PDL
Bid / ask spread
—
Quote not published
Session volume
1.47M
Avg 1.90M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.25%
-4.2%
1M
-4.83%
-6.0%
3M
+5.32%
+0.8%
6M
+107.57%
+89.4%
YTD
+150.94%
+136.7%
1Y
+327.90%
+311.5%
3Y
+622.07%
+539.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RVMD open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-115.84K
Net selling
Buy transactions
21
509.90K shares
Sell transactions
23
625.74K shares
Net transactions
+44
Buys less sells
Sell : buy shares
1.2 : 1
Mixed
Insider-held shares
3.97M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 29, 26 | SANDLER ALAN B. Officer |
SELL | 6.31K | $1.28M | Direct |
| Sep 29, 26 | SANDLER ALAN B. Officer |
CONVERSION | 6.00K | $353.04K | Direct |
| Sep 25, 26 | CISLINI JEFFREY TODD General Counsel |
SELL | 765 | $158.60K | Direct |
| Sep 25, 26 | MANCINI ANTHONY Officer |
SELL | 3.71K | $743.28K | Direct |
| Sep 25, 26 | MANCINI ANTHONY Officer |
CONVERSION | 3.12K | $104.93K | Direct |
| Sep 22, 26 | ANDERSON ELIZABETH M Director |
SELL | 10.14K | $1.96M | Direct |
| Sep 22, 26 | ANDERSON ELIZABETH M Director |
CONVERSION | 5.07K | $5.68K | Direct |
| Sep 18, 26 | MANCINI ANTHONY Officer |
SELL | 1.76K | $347.40K | Direct |
| Sep 11, 26 | KELSEY STEPHEN MICHAEL Officer |
SELL | 92.53K | $18.72M | Direct |
| Sep 11, 26 | KELSEY STEPHEN MICHAEL Officer |
CONVERSION | 92.53K | $3.86M | Direct |
| Sep 10, 26 | MANCINI ANTHONY Officer |
SELL | 15.45K | $3.15M | Direct |
| Sep 10, 26 | MANCINI ANTHONY Officer |
CONVERSION | 9.36K | $314.78K | Direct |
| Sep 8, 26 | KIM LORENCE H Director |
SELL | 17.09K | $3.59M | Indirect |
| Aug 31, 26 | KIM LORENCE H Director |
SELL | 56.00K | $11.38M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANDERS JACK LEE |
Chief Financial Officer | 123.27K | Sale |
BORISY ALEXIS |
Director | 2.34M | Stock Award(Grant) |
GOLDSMITH MARK A |
Chief Executive Officer | — | Sale |
HORN MARGARET A |
Chief Operating Officer | 154.65K | Sale |
HORNING SANDRA |
Director | 97.77K | Stock Award(Grant) |
KELSEY STEPHEN MICHAEL |
Officer | 291.88K | Sale |
LIN WEI |
Officer | 101.37K | Sale |
SANDLER ALAN B. |
Officer | 52.56K | Sale |
SCHROEDER THILO |
Director | — | Purchase |
WANG XIAOLIN |
Officer | 116.06K | Sale |
Fundamentals
Market cap$42.84B
Enterprise value$40.09B
Revenue (TTM)—
Gross profit$-1.30B
EBITDA$-1.62B
Net income$-1.77B
EPS (TTM)$-8.53
Free cash flow$-711.61M
Total cash$3.94B
Total debt$1.19B
Book value / share$12.17
Shares outstanding214.34M
Float184.61M
Short % of float4.76%
Dividend yield0.00%
Beta (5Y)1.40
Valuation & profitability ratios
Trailing P/E—
Forward P/E-34.98
PEG ratio—
Price / sales—
Price / book16.43
EV / revenue—
EV / EBITDA-24.78
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-79.09%
Return on assets-30.12%
Debt / equity45.68
Current ratio11.38
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $11.58M | $35.38M | — |
| Operating revenue | $0 | $0 | $11.58M | $35.38M | — |
| Research & development | $987.33M | $592.23M | $423.14M | $253.07M | +66.7% |
| Selling, general & admin | $195.04M | $97.30M | $75.62M | $40.59M | +100.5% |
| Total operating expense | $1.18B | $689.52M | $498.76M | $293.66M | +71.5% |
| Operating income | -$1.18B | -$689.52M | -$487.19M | -$258.28M | -71.5% |
| Net interest income | $66.46M | $86.88M | $47.48M | $9.15M | -23.5% |
| Pre-tax income | -$1.13B | -$600.85M | -$439.89M | -$249.13M | -88.3% |
| Tax provision | $0 | -$753.00K | -$3.52M | -$420.00K | +100.0% |
| Net income | -$1.13B | -$600.09M | -$436.37M | -$248.71M | -88.5% |
| Net income to common | -$1.13B | -$600.09M | -$436.37M | -$248.71M | -88.5% |
| Basic EPS | -5.95 | -3.58 | -3.86 | -3.08 | -66.2% |
| Diluted EPS | -5.95 | -3.58 | -3.86 | -3.08 | -66.2% |
| EBIT | -$1.11B | -$600.85M | -$439.89M | -$258.28M | -84.3% |
| EBITDA | -$1.09B | -$589.02M | -$430.58M | -$248.62M | -85.1% |
| Basic shares | 190.13M | 167.74M | 113.15M | 80.63M | +13.3% |
| Diluted shares | 190.13M | 167.74M | 113.15M | 80.63M | +13.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $383.75M | $543.06M | $696.15M | $161.41M | — | -29.3% |
| Cash & short-term investments | $2.03B | $2.29B | $1.85B | $644.94M | — | -11.5% |
| Accounts receivable | — | $0 | $1.25M | $4.67M | $5.93M | — |
| Total current assets | $2.08B | $2.33B | $1.88B | $660.18M | — | -10.9% |
| Property, plant & equipment | $165.28M | $141.82M | $100.01M | $73.74M | — | +16.5% |
| Goodwill & intangibles | $70.41M | $71.28M | $72.35M | $73.42M | — | -1.2% |
| Total assets | $2.35B | $2.56B | $2.06B | $811.93M | — | -8.0% |
| Total current liabilities | $290.42M | $163.91M | $143.85M | $61.98M | — | +77.2% |
| Total debt | $158.70M | $135.84M | $87.94M | $64.20M | — | +16.8% |
| Total liabilities | $723.21M | $293.10M | $235.51M | $126.74M | — | +146.7% |
| Retained earnings | -$2.87B | -$1.74B | -$1.14B | -$701.34M | — | -65.1% |
| Shareholder equity | $1.63B | $2.27B | $1.83B | $685.19M | — | -28.0% |
| Working capital | $1.78B | $2.16B | $1.74B | $598.20M | — | -17.5% |
| Net tangible assets | $1.56B | $2.19B | $1.75B | $611.77M | — | -28.9% |
| Shares issued | 197.00M | 185.90M | 164.67M | 90.41M | — | +6.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$1.13B | -$600.09M | -$436.37M | -$248.71M | -88.5% |
| Depreciation & amortisation | $16.56M | $11.82M | $9.31M | $9.66M | +40.0% |
| Stock-based compensation | $118.39M | $79.20M | $61.77M | $31.20M | +49.5% |
| Change in working capital | $86.82M | $406.00K | $36.75M | -$13.49M | +21,285.0% |
| Operating cash flow | -$897.74M | -$557.44M | -$350.57M | -$224.40M | -61.0% |
| Capital expenditure | -$15.99M | -$10.31M | -$7.73M | -$10.82M | -55.1% |
| Investing cash flow | $118.06M | -$554.39M | -$342.60M | -$24.12M | +121.3% |
| Financing cash flow | $621.52M | $959.41M | $1.23B | $301.43M | -35.2% |
| Free cash flow | -$913.73M | -$567.74M | -$358.30M | -$235.22M | -60.9% |
| End cash position | $388.60M | $546.76M | $699.18M | $163.15M | -28.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $394.92M | $343.97M | $294.94M | $262.51M | $224.13M | +14.8% |
| Selling, general & admin | $110.21M | $101.25M | $66.68M | $52.76M | $40.58M | +8.9% |
| Total operating expense | $505.13M | $445.22M | $361.63M | $315.27M | $264.71M | +13.5% |
| Operating income | -$505.13M | -$445.22M | -$361.63M | -$315.27M | -$264.71M | -13.5% |
| Net interest income | $11.80M | $7.31M | $9.36M | $10.65M | $21.54M | +61.4% |
| Pre-tax income | -$644.37M | -$453.82M | -$364.89M | -$305.21M | -$247.79M | -42.0% |
| Net income | -$644.37M | -$453.82M | -$364.89M | -$305.21M | -$247.79M | -42.0% |
| Net income to common | -$644.37M | -$453.82M | -$364.89M | -$305.21M | -$247.79M | -42.0% |
| Basic EPS | -3.06 | -2.29 | -1.86 | -1.61 | -1.31 | -33.6% |
| Diluted EPS | -3.06 | -2.29 | -1.86 | -1.61 | -1.31 | -33.6% |
| EBIT | -$620.59M | -$441.62M | -$352.96M | -$293.78M | -$246.92M | -40.5% |
| EBITDA | -$611.55M | -$437.08M | -$348.25M | -$289.44M | -$243.12M | -39.9% |
| Basic shares | 210.89M | 198.10M | 196.67M | 189.23M | 188.58M | +6.5% |
| Diluted shares | 210.89M | 198.10M | 196.67M | 189.23M | 188.58M | +6.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $815.43M | $440.94M | $383.75M | $217.44M | $402.44M | +84.9% |
| Cash & short-term investments | $3.94B | $1.91B | $2.03B | $1.93B | $2.14B | +106.4% |
| Total current assets | $4.03B | $1.97B | $2.08B | $1.98B | $2.18B | +104.7% |
| Property, plant & equipment | $162.45M | $161.37M | $165.28M | $167.38M | $147.05M | +0.7% |
| Goodwill & intangibles | $70.41M | $70.41M | $70.41M | $70.48M | $70.74M | 0.0% |
| Total assets | $4.32B | $2.25B | $2.35B | $2.25B | $2.43B | +91.8% |
| Total current liabilities | $354.06M | $289.60M | $290.42M | $245.62M | $184.53M | +22.3% |
| Long-term debt | $487.43M | — | — | — | — | — |
| Total debt | $641.93M | $156.63M | $158.70M | $158.46M | $132.79M | +309.8% |
| Total liabilities | $1.72B | $753.82M | $723.21M | $655.02M | $564.20M | +127.8% |
| Retained earnings | -$3.97B | -$3.32B | -$2.87B | -$2.50B | -$2.20B | -19.4% |
| Shareholder equity | $2.61B | $1.50B | $1.63B | $1.60B | $1.87B | +73.8% |
| Working capital | $3.67B | $1.68B | $1.78B | $1.73B | $1.99B | +118.9% |
| Net tangible assets | $2.54B | $1.43B | $1.56B | $1.53B | $1.79B | +77.4% |
| Shares issued | 214.24M | 200.18M | 197.00M | 189.71M | 186.90M | +7.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$1.10B | -$453.82M | -$364.89M | -$305.21M | -$247.79M | -142.0% |
| Depreciation & amortisation | $9.04M | $4.54M | $4.70M | $4.34M | $3.80M | +99.2% |
| Stock-based compensation | $154.30M | $87.30M | $33.70M | $30.78M | $28.83M | +76.7% |
| Change in working capital | -$1.87M | -$16.95M | $32.25M | $56.44M | -$4.30M | +89.0% |
| Operating cash flow | -$741.48M | -$354.17M | -$274.24M | -$207.31M | -$221.76M | -109.4% |
| Capital expenditure | -$3.82M | -$1.54M | -$1.93M | -$3.35M | -$7.45M | -148.6% |
| Investing cash flow | -$1.49B | $172.62M | $74.88M | $24.85M | $34.28M | -960.9% |
| Financing cash flow | $2.66B | $238.74M | $365.66M | -$1.59M | $256.58M | +1,013.8% |
| Free cash flow | -$745.31M | -$355.70M | -$276.16M | -$210.66M | -$229.21M | -109.5% |
| End cash position | $820.29M | $445.80M | $388.60M | $222.30M | $406.35M | +84.0% |
Options analytics
Put / call volume
0.55
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
140.00
-30.0% from spot
ATM implied vol
0.2%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
454
Contracts, this expiry
Put volume
251
Contracts, this expiry
Heaviest call OI
110.00
0 contracts
Heaviest put OI
130.00
3 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -2.06 | -3.06 | -48.8% |
| Mar 2026 | -1.84 | -2.29 | -24.6% |
| Dec 2025 | -1.56 | -1.86 | -18.9% |
| Sep 2025 | -1.41 | -1.61 | -14.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -2.38 | 21 | $23.24M | 0.0% |
| Next quarter | -1.97 | 21 | $156.86M | 0.0% |
| Current year | -9.61 | 23 | $188.45M | 0.0% |
| Next year | -5.71 | 23 | $1.25B | +565.5% |
Analyst targets & ownership
Mean target$258.79
High target$320.00
Low target$179.00
Implied upside29.92%
Analyst count23
ConsensusSTRONG BUY
Strong buy / Buy5 / 18
Hold1
Sell / Strong sell0 / 0
Held by insiders1.85%
Held by institutions101.26%
Institutions holding947
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
202.71
-1.73% from price
SMA 20
201.07
-0.60% from price
SMA 50
202.99
-1.54% from price
SMA 100
185.72
+7.26% from price
SMA 200
147.20
+35.78% from price
EMA 12
202.86
-1.81% from price
EMA 26
202.48
-1.62% from price
EMA 50
198.70
+0.25% from price
RSI (14)
46.8
Neutral
MACD (12,26,9)
0.38
Hist 0.52
ATR (14)
7.67
3.84% of price
Realised vol 30D
34.3%
Annualised
Bollinger upper
212.22
20, 2σ
Bollinger lower
189.92
20, 2σ
50 / 200 cross
Golden
202.99 vs 147.20
Trend bias
Above 200
+35.78%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.09
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
34.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-25.0%
Peak to trough
Max drawdown 5Y
-56.9%
Peak to trough
ATR 14
7.67
3.84% of price
Beta (reported)
1.40
5Y monthly, from filing
Short interest
Shares short
9.67M
Prior 9.72M
Change vs prior
-0.5%
Shorts covering
% of float
4.76%
Normal
% of shares out
4.51%
Against total outstanding
Days to cover
5.5
Crowded exit
Float
184.61M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 28, 26 | Brookline Capital | INITIATED | — | Buy |
| Sep 21, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Sep 10, 26 | Morgan Stanley | INITIATED | — | Overweight |
| Sep 9, 26 | Stifel | MAINTAINED | Buy | Buy |
| Aug 31, 26 | Needham | MAINTAINED | Buy | Buy |
| Aug 28, 26 | UBS | MAINTAINED | Buy | Buy |
| Aug 28, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 27, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Aug 27, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 27, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 27, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 27, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-01
Corporate Changes & Voting Matters
8-K · 2026-08-26
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-22
Corporate Changes & Voting Matters
8-K · 2026-05-06
Proxy Statements
DEFA14A · 2026-04-28
Proxy Statements
DEF 14A · 2026-04-27
Corporate Changes & Voting Matters
8-K · 2026-04-17
Headlines
First-Line RAS G12D Pancreatic Cancer Trial Launch Could Be A Game Changer For Revolution Medicines (RVMD)
Simply Wall St. · 1h ago
Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers
Investor's Business Daily · 9h ago
Revolution Medicines Begins Phase 3 Trial of Rasonque Combination in Pancreatic Cancer
MT Newswires · 2d ago
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
GlobeNewswire · 2d ago
Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says
MT Newswires · 9d ago
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
CNW Group · 9d ago
Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?
Insider Monkey · 12d ago
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Motley Fool · 12d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.